Lenvatinib Combo Improves Responses Vs Sunitinib in Clear Cell RCC
Pembrolizumab plus lenvatinib yields clinically relevant efficacy in clear cell renal cell carcinoma subgroups based on site of metastasis and number of metastatic sites in the phase 3 CLEAR trial.
Teclistamab Produces Responses in Pretreated R/R Multiple Myeloma
Data suggest a role for TIGIT blockade or CD25-positive cell depletion to enhance teclistamab’s efficacy in relapsed/refractory multiple myeloma.
Addition of Dual Checkpoint Blockade Inhibition Improves PFS in Ovarian Cancer
Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.
Lenvatinib Following Initial Immunotherapy Improves Survival in Liver Cancer Subtype
Lenvatinib yields survival benefit in hepatocellular carcinoma following progression on immunotherapy.
Promising Efficacy Seen With Addition of Orelabrutinib to R-CHOP in Non-GCB DLBCL
In patients with non-germinal center B cell–like diffuse large B-cell lymphoma, the combination of orelabrutinib plus R-CHOP revealed an overall response rate of 86.4%.
Overall Survival Benefit Demonstrated With Abemaciclib Plus Aromatase Inhibitors in HR+/HER2– Breast Cancer
Abemaciclib prolonged overall survival when added to a nonsteroidal aromatase inhibitor in hormone receptor–positive, HER2–negative breast cancer, according to updated findings from the MONARCH 3 trial presented at 2022 ESMO.
Pembrolizumab Plus Lenvatinib Confers Promising Efficacy in Malignant Pleural Mesothelioma
Results from the phase 2 PEMMELA trial revealed positive treatment benefits in patients with malignant pleural mesothelioma who were given pembrolizumab plus lenvatinib.
Lacrotrectinib Leads to Prolonged Response in NTKR+ Tumors
Across 3 clinical trials, investigators continued to observe durable responses with larotrectinib, which showed the importance of NTRK gene fusion testing in patients with various cancer types.
Ivosidenib Plus Azacitidine Yields Significant Treatment Benefit in IDH1-Mutant AML
Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.
Avelumab Up Front Plus BSC Prolongs OS in Advanced Urothelial Carcinoma Over BSC Alone
The JAVELIN Bladder 100 trial demonstrated that avelumab plus best supportive care prolonged overall survival vs best supportive care alone for patients with advanced urothelial carcinoma.
Statistically Significant EFS Boost Observed With Nivolumab/Chemo for Resectable NSCLC
Results of a phase 3 trial comparing neoadjuvant nivolumab plus chemotherapy denoted benefit vs chemotherapy alone for patients with resectable non-small cell lung cancer.
H3K27M+ Diffuse Intrinsic Pontine Gliomas Derive Benefit from GD2-Directed CAR T-cell Therapy
Children and young adults with H3K27M-positive diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas saw a clinical benefit when treated with GD2-directed chimeric antigen receptor T cell therapy.
2 Clarke Drive Cranbury, NJ 08512